Chemotherapy Effects on Blood Stem Cells in Lung Cancer
Author Information
Author(s): E. Shimizu, A. Yamamoto, Y. Takahashi, K. Maniwal, S. Yoshida, J. Mukail, Y. Takaue, T. Ogural
Primary Institution: The University of Tokushima School of Medicine
Hypothesis
Does alternating combination chemotherapy increase hematopoietic progenitor cells in patients with small cell lung cancer?
Conclusion
The study found that the PVP phase of chemotherapy led to a rebound increase in blood stem cells, while the CAV phase did not.
Supporting Evidence
- Patients displayed a rebound increase in blood stem cells during the PVP phase of chemotherapy.
- None of the patients showed a rebound increase during the CAV phase.
- The study suggests optimal timing for harvesting blood stem cells after chemotherapy.
Takeaway
Doctors tested a new way to treat lung cancer and found that one part of the treatment helped increase special blood cells that help the body recover.
Methodology
Five male patients with small cell lung cancer received alternating chemotherapy regimens, and their blood stem cell levels were measured over time.
Limitations
The study had a small sample size and did not include patients who had received prior chemotherapy.
Participant Demographics
All five participants were male, with a median age of 61 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website